Tag Archives: Clostridium difficile

The C Diff Foundation Has Declared an Urgent Need to Raise Clostridium difficile Infection Clinical Trial Awareness Worldwide

TAMPA, Fla. /ScoopCloud/ -- The C Diff Foundation announced today that their organization has implemented a global campaign to raise awareness of Clostridioides difficile clinical trials, clinical studies, clinical research and observational studies evaluating interventions for C. difficile prevention, treatments, and environmental safety.

Clostridioides difficile is also known as C.difficile, C.diff, CDI (Clostridioides difficile infection), CDAD (Clostridioides difficile-associated disease) and formally called Clostridium difficile.

In the USA: Nearly half a million Americans suffer from Clostridioides difficile (C. diff.) infections in a single year according to a study released in 2015 by the Centers for Disease Control and Prevention (CDC). Approximately 29,000 patients died within 30 days of the initial diagnosis of C. difficile. About 15,000 deaths were estimated to be directly attributable to C. difficile infections making it a very important cause of infectious disease death in the United States.

"The broad range of new therapies for Clostridium difficile (C.difficile) is being intensely studied in several essential global clinical trials. This continued research underpins the current clinical needs with both preventing and treating C.difficile," stated Glenn S. Tillitson, Ph.D., FRSM, FCCP.

Individuals volunteer to participate in clinical trials in hopes of improving their own health, to access treatments that might not be available otherwise, often because they are new and not yet widely available. They help others by contributing to advances in medicine. There can also be potential risks participating in clinical trials and clinical studies. All of the known risks associated with a particular trial and or study will be discussed during the informed consent process. It will be thoroughly explained in the informed consent document that a volunteer will receive from the research staff prior to participating in any study.

To learn more about clinical research (e.g., Clostridioides difficile formally Clostridium difficile, also known as C.diff. C.difficile. CDI, CDAD) visit the U.S. Food and Drug Administration https://www.fda.gov/ or telephone 1-800-835-4709, and visit https://clinicaltrials.gov/.

"Clinical trials are vital to improving our knowledge about how best to prevent and treat C. difficile infections. Informing patients of clinical trials is important, and in recent years several clinical trials have led to significant improvements in the treatments available for patients with C. difficile infections. Clinical trials are a vital way of making progress in our search for new therapies to prevent and treat a CDI," stated Mark Wilcox, MD, FRCPath, Consultant Microbiologist, Head of Microbiology and Academic Lead of Pathology Leeds Teaching Hospitals, Professor of Medical Microbiology University of Leeds Institute of Biomedical and Clinical Sciences, Lead on Clostridium difficile for Public Health England, UK.

About the U.S. Food and Drug Administration (FDA):

The FDA is responsible for protecting the public health by assuring that foods are safe, wholesome, sanitary and properly labeled; ensuring that human and veterinary drug, and vaccines and other biological products and medical devices intended for human use are safe and effective. FDA's responsibilities extend to the 50 United States, the District of Columbia, Puerto Rico, Guam, the Virgin Islands, American Samoa, and other U.S. territories and possessions.

About ClinicalTrials.gov:

ClinicalTrials.gov is a Web-based resource that provides patients, their family members, health care professionals, researchers, and the public with easy access to information on publicly and privately supported clinical studies on a wide range of diseases and conditions.

About the C Diff Foundation:

The C Diff Foundation, a 501(c)(3) non-profit, founded in 2012 with a global mission of providing education for C.difficile infection prevention, treatments, environmental safety and support through research being conducted by the government, industry, and academia and provide better advocacy on behalf of patients, healthcare professionals, and researchers worldwide.

For information please visit http://www.cdifffoundation.org/.

The C Diff Foundation announced today that their organization has implemented a global campaign to raise awareness of Clostridioides difficile clinical trials, clinical studies, clinical research and observational studies evaluating interventions for C. difficile prevention, treatments, and environmental safety.

Related link: https://cdifffoundation.org/

C Diff Foundation Recognizes Rebiotix CEO with 2019 ‘Above and Beyond’ Award

NEW PORT RICHEY, Fla. /ScoopCloud/ -- The C. Diff Foundation Board of Directors announced today that the 2019 "Above and Beyond" Award will be presented to Rebiotix CEO Lee Jones in Roseville, Minnesota. The award, given to one recipient annually, is given to a person or organization that show extraordinary dedication to C. diff patient safety, advocacy, and overall drive to improve the lives of those impacted by the infection.

"We are very proud to recognize Ms. Jones with our "Above and Beyond" award," said C. Diff Foundation Founder and President, Nancy Caralla. "Lee's dedication to the entire C. diff community of patients, family members, and physicians hasn't wavered since the founding of Rebiotix in 2011. She is a true example of what can happen when focusing on patient well-being drives new approaches to healthcare."

The award will be presented by the Foundation's Vice President, Scott Battles, and Treasurer Angelo Ortiz at the Rebiotix facility.

"It's an honor to receive this award from the C. Diff Foundation," said Ms. Jones. "The purpose of starting Rebiotix was to bring the power of the microbiome to the clinic in a scientifically sound, quality-controlled way to help patients. We stand with the Foundation in believing that patient well-being should be at the core of all that we do, from clinical trials to exploring new scientific landscapes within the microbiome space."

About the C Diff Foundation:

The C Diff Foundation is a non-profit, 501(c)(3) organization established in 2012. It is comprised of 100% volunteering professionals dedicated to supporting public health through education and advocacy for C. difficile infection prevention, treatments, environmental safety and support world-wide. The Foundation's CEO and founder is a nurse inspired to create the foundation after witnessing the loss of her father to CDI, as well as suffering from the infection herself. The C Diff Foundation members, with their volunteer patient advocates, successfully "raise C. diff awareness" locally and in over fifty-six (56) countries and host a U.S. nation-wide hotline (1-844-FOR-CDIF) to support healthcare providers, patients and families through the difficulties of a C. diff infection. Learn more: https://cdifffoundation.org/

About Rebiotix Inc.:

Rebiotix Inc., part of the Ferring Pharmaceuticals Group, is a late-stage clinical microbiome company focused on harnessing the power of the human microbiome to revolutionize the treatment of debilitating diseases. Rebiotix possesses a deep and diverse clinical pipeline, with its lead drug candidate, RBX2660, in Phase 3 clinical development for the prevention of recurrent Clostridium difficile (C. diff) infection. RBX2660 has been granted Fast Track, Orphan and Breakthrough Therapy designation from the FDA for its potential to prevent recurrent C. diff infection.

Rebiotix's clinical pipeline also features RBX7455, a lyophilized, room temperature stable oral capsule formulation. Rebiotix is also targeting several other disease states with drug products built on its pioneering Microbiota Restoration Therapy(tm) platform. For more information on Rebiotix and its pipeline of human microbiome-directed therapies, visit https://www.rebiotix.com/

Twitter: @cdiffFoundation #CdiffInfection #Clostridiumdifficile @Rebiotix

The C. Diff Foundation Board of Directors announced today that the 2019 "Above and Beyond" Award will be presented to Rebiotix CEO Lee Jones in Roseville, Minnesota. The award, given to one recipient annually, is given to a person or organization that show extraordinary dedication to C. diff patient safety, advocacy, and overall drive to improve the lives of those impacted by the infection.

Related link: https://cdifffoundation.org/

C Diff Foundation Presents Award to CutisPharma in Recognition of Contribution to C. diff. Community

NEW PORT RICHEY, Fla. /ScoopCloud/ -- The C Diff Foundation announced today that it presented CutisPharma, Inc., its "Making a Difference" award as a special recognition of the significant contribution that CutisPharma has made to the C.diff. Community: helping the advancement of C.diff. awareness as well as expanding treatment options for C.diff. patients.

The award was presented at CutisPharma's celebration of its upcoming launch of FIRVANQ(TM), recently approved by the FDA for the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. Upon launch, FIRVANQ(TM) will be the only FDA-approved oral vancomycin solution treatment commercially available, improving patient access and reducing pharmacist burden by no longer having to compound oral liquid formulations.

"CutisPharma has been a committed partner of our Foundation and has furthered our mission to increase C.diff. awareness and support the research and development of new treatment options," said Nancy C. Caralla, Foundress and Executive Director of the C Diff Foundation. "In recognition of CutisPharma's efforts, we are pleased to grant them the 'Making a Difference' award at this special moment in the Company's 20th anniversary year."

"We are very grateful to receive such a special distinction from the C Diff Foundation," said Neal I. Muni, MD, MSPH, and Chief Executive Officer of CutisPharma. "For 20 years, we have been committed to improving the lives of patients who are not well-served by existing therapies and would benefit from high-quality, cost-effective new treatment options. We greatly value our partnership with the C Diff Foundation and look forward to continuing to support their mission."

In the USA: Nearly half a million Americans suffer from Clostridium difficile (C. diff.) infections in a single year according to a study released in 2015 by the Centers for Disease Control and Prevention (CDC). Approximately 29,000 patients died within 30 days of the initial diagnosis of C. difficile. Of those, about 15,000 deaths were estimated to be directly attributable to C. difficile infections making C. difficile a very important cause of infectious disease death in the United States.

About the C Diff Foundation:

The C Diff Foundation, a 501(c)(3)non-profit organization, established in 2012, is comprised of 100 percent volunteering professionals dedicated to supporting public health initiatives for C. difficile infection prevention, treatments, environmental safety, and support worldwide. For more information, visit: https://cdifffoundation.org/.

About CutisPharma:

CutisPharma, Inc., based in Wilmington, Mass., is privately held, specialty pharmaceutical company that has been the industry leader for 20 years in providing innovative solutions to pharmacists. CutisPharma's FIRST(r) Unit-of-Use Compounding Kits have benefited millions of patients who are unable to swallow conventional oral dosage forms such as tablets and capsules and whose needs are not served by commercially available therapies. The Company's first FDA-approved Kit, FIRVANQ(TM), will allow significantly broader patient access, convenience to pharmacists and patients alike by reducing the need for compounding, and serve as a potential cost-saving option to existing treatments. For more information, visit: https://cutispharma.com/.

The C Diff Foundation today announced that it presented CutisPharma, Inc., its "Making a Difference" award as a special recognition of the significant contribution that CutisPharma has made to the C.diff. Community: helping the advancement of C.diff. awareness as well as expanding treatment options for C.diff. patients.

Related link: https://cdifffoundation.org/

Clifford McDonald, MD and Alison Laufer-Halpin, Ph.D., of the CDC Discuss the Human Microbiome on C. diff. Spores and More

ATLANTA, Ga. /ScoopCloud/ -- C Diff Foundation's "C. diff. Spores and More Global Broadcasting Network" is honored to announce Doctors McDonald and Laufer-Halpin as our guest speakers on July 25, 2017 at 10 a.m. PT / 1 p.m. ET on C Diff Radio (www.cdiffradio.com).

These leading topic experts will be discussing significant ways to unlock the mysteries of the human microbiome; how it affects our health, the immune system, and why it is so important to protect it.

As part of the Centers for Disease Control and Prevention (CDC) efforts to protect patients and slow antibiotic-resistance, the CDC is investing in research to discover and develop new ways to prevent antibiotic-resistant infections.

Learn more about C Diff Radio at: http://www.cdiffradio.com/.

About the C Diff Foundation:

The C Diff Foundation, a 501(c)(3) non-profit, founded in 2012 by Nancy C. Caralla, a nurse who was diagnosed and treated for Clostridium difficile (C. diff.) infections.

Through her own journey and the loss of their father to C. difficile infection involvement, Nancy recognized the need for greater awareness through education about research being conducted by the government, industry, and academia and better advocacy on behalf of patients, healthcare professionals, and researchers worldwide working to address the public health threat posed by this devastating infection.

For information please visit https://cdifffoundation.org/.

More information and media queries: info@cdifffoundation.org

C Diff Foundation's "C. diff. Spores and More Global Broadcasting Network" is honored to announce Doctors McDonald and Laufer-Halpin as our guest speakers on July 25, 2017 at 10 a.m. PT / 1 p.m. ET on C Diff Radio.

Related link: https://cdifffoundation.org/

C Diff Foundation Announces Scholarship Program to Support Health Care Students

TAMPA, Fla. /ScoopCloud/ -- The C Diff Foundation is pleased to announce the Michael and Helen Caralla, Sr. Educational Scholarship program. The scholarship program is to help health care students succeed and reach their educational goals.

To apply for a C Diff Foundation; Michael and Helen Caralla, Sr. Educational Scholarship, the applicant must submit an application by May 1 of each calendar year. The C Diff Foundation selection committee chooses application recipients based on a submitted essay, letters of recommendation, a willingness to complete the Volunteer Service project to promote C. difficile infection awareness requirement, and financial need.

Awards consist of annual scholarships that range in value from $750 to $1,500 USD. Recipients must reapply each year they attend post-secondary school and will be chosen based on their academic progress and mentoring performance.

To be eligible for a Michael and Helen Caralla, Sr. Educational Scholarship the applicant must be:
* A student and a high school graduate or have a General Educational Development a.k.a. General Educational Diploma (GED).
* Enrolled full-time at an accredited post-secondary educational institution during the 2017-2018 academic year (If a foreign student is applying and is chosen, the educational scholarship awarded amount will be converted from USD to the educational institute location foreign currency exchange rate and rounded up to the nearest whole dollar).
* Maintain full-time status throughout the 2017-2018 academic year in order to remain eligible.
* Willing to complete a minimum of 50 volunteer hours promoting C. difficile infection prevention, treatments, and environmental safety awareness in their local communities per academic year awarded the educational scholarship.

C. difficile infections can be acquired and diagnosed in infants and across the life-span with a higher risk involving our senior citizens and that is why it is imperative to learn about a C. difficile infection, its most common symptoms, the treatments available, and environmental safety products to prevent the spread of this spore-bacteria and to help reduce C. difficile infection recurrences.

"When you apply to become a C Diff Foundation Scholar, you are taking the first step to determine your own future. The C Diff Foundation Scholars are individuals motivated and dedicated to making a difference in the health care community. We are excited to offer a scholarship program to help support health care students to advance their career path through the Michael and Helen Caralla, Sr. educational scholarship, a program in memory of our loving parents," states Nancy C Caralla, Executive Director.

About the C Diff Foundation:

The C Diff Foundation, a 501(c)(3) non-profit, founded in 2012 by Nancy C Caralla, a nurse diagnosed and treated for Clostridium difficile (C. diff.) infections.

Through her own CDI journeys and witnessing the passing of her father, diagnosed with sepsis secondary to C. difficile infection involvement, Nancy recognized the need for greater awareness through education, the research being conducted by the government, industry, and academia and better advocacy on behalf of patients, healthcare professionals, and researchers worldwide working to address the public health threat posed by this devastating infection.

For additional Scholar Applicant information, visit the C Diff Foundation website: https://cdifffoundation.org/scholarship-eligibility/

Media Coordinator:
Denise Graham, RN, CIC
info@cdifffoundation.org

Twitter: @cdiffFoundation #CdiffScholar

*PHOTO for media: Send2Press.com/mediaboom/17-0711s2p-caralla-300dpi.jpg
*Photo Caption: Michael and Helen Caralla, Sr.

The C Diff Foundation is pleased to announce the Michael and Helen Caralla, Sr. Educational Scholarship program. The scholarship program is to help health care students succeed and reach their educational goals.

Related link: https://cdifffoundation.org/

‘C. diff. Science’ Honors Professionals Dedicated to Clostridium difficile Research and Development

TAMPA, Fla. /ScoopCloud/ -- The C Diff Foundation hosts "C. diff. Science" on Sept. 14 to honor professionals dedicated to the scientific research and development in the Clostridium difficile (C. difficile, C. diff.) community worldwide, chaired by Professor Simon M. Cutting, PhD, of Molecular Microbiology at Royal Holloway, University of London.

The free live webinar will take place from 8 a.m. - 12 p.m. ET, Sept. 14, 2017.

Professor Cutting, Event Chair and guest presenter, shares the platform with seven fellow scientists focused on their contributions involving the most common pathogen identified, and leading healthcare-associated infection (HAI) - Clostridium difficile.

C. difficile infections can be acquired and diagnosed in infants and across the life-span with a higher risk involving our senior citizens and that is why it is imperative to learn about a C. difficile infection, its most common symptoms, the treatments available, and environmental safety products to prevent the spread of this spore-bacteria and to help reduce C. difficile infection recurrences.

"On September 14th fellow professionals in the C. diff. community, and those who share a common interest, will have the opportunity to gain knowledge from scientists around the globe who have dedicated their professional lives researching and developing new concepts, new theories, and the progress towards a better understanding - pursuing future developments in Clostridium difficile (a.k.a., C. difficile, C.diff.) infection prevention, treatments, and environmental safety products worldwide," states Nancy C Caralla, Executive Director.

About the C Diff Foundation:

The C Diff Foundation, a 501(c)(3) non-profit, founded in 2012 by Nancy C Caralla, a nurse diagnosed and treated for Clostridium difficile (C. diff.) infections.

Through her own journeys and witnessing the passing of her father diagnosed with sepsis secondary to C. difficile infection involvement, Nancy recognized the need for greater awareness through education, the research being conducted by the government, industry, and academia and better advocacy on behalf of patients, healthcare professionals, and researchers worldwide working to address the public health threat posed by this devastating infection.

For webinar information contact event coordinators: info@cdiffscience.org and visit the event website: http://cdiffscience.org/ to register for this free webinar.

For C Diff Foundation information please visit: https://cdifffoundation.org/.

Media Contact Person:
Nancy Caralla
ncaralla@cdifffoundation.org

*LOGO: https://cdifffoundation.files.wordpress.com/2013/06/cdifflogoadjdtrd.jpg

Twitter: @cdiffFoundation #CDiffScience

The C Diff Foundation hosts "C. diff. Science" on Sept. 14 to honor professionals dedicated to the scientific research and development in the Clostridium difficile (C. difficile, C. diff.) community worldwide, chaired by Professor Simon M. Cutting, PhD, of Molecular Microbiology at Royal Holloway, University of London.

Bake Sale to Raise C. diff. Awareness Starts in Florida Before Volunteers Roll-out Worldwide

TAMPA, Fla. /ScoopCloud/ -- C Diff Foundation announces its "Bake Sale for C.diff. Awareness," a month-long campaign beginning May 2017 in Florida and continuing in N.J., N.C., and across the USA to India, and Italy featuring education and advocacy on health care topics pertaining to the most common pathogen identified as a leading healthcare-associated infection (HAI) in U.S. hospitals alone: Clostridium difficile.

You know how when you are trying to promote Clostridium difficile (C.diff.) awareness, you run into obstacles - such as information resistance and lack of concern.

We have experienced it, learned from it, and developed new roads to successfully accomplish the goal to effectively promote C.difficile infection (CDI) awareness prevention, treatments, environmental safety, and support available.

Nearly half a million Americans suffer from Clostridium difficile (C. diff.) infections in a single year according to a study released February 2015 by the Centers for Disease Control and Prevention (CDC). About 15,000 deaths were estimated to be directly attributable to C. diff. infections.

Previous studies indicate that C. diff. has become the most common microbial cause of healthcare-associated infections found in U.S. hospitals driving up costs to $4.8 billion each year.

The C Diff Foundation takes it to a different level to promote the message and receive the audience's nod generously donating funds to support educational patient programs offered. We do this by having residents share in a common-interest event - a "Bake Sale for C. diff. Awareness."

Who are the audiences? They are you, neighbors, local health care professionals, local service operators -- both students and faculty -- and individuals with a will to join the events to learn about a C. difficile infection because it can be acquired by anyone and has no boundaries.

At first the residents, health care professionals, and local service professionals show resistance to listen about how a gastrointestinal infection, that they have never experienced, can cause such pain and tragic losses.

Once they are introduced to Kathy, Nancy, Lisa, Roy, Scott, Angelo, Tonia, Renetta, Gary, Deborah, and thousands of other Clostridium difficile (C.diff.) Survivors (www.cdiffsurvivors.org) and hear their heart-breaking C. difficile infection journeys - the door swings open and the understanding takes hold.

As a result, we witness an exchange of important information with the positive outcome of understanding how dangerous a C. difficile infection can be, how important it is to have a conversation with health care providers about the use of antibiotics to treat respiratory, urinary, and dental symptoms, how to manage the care of a C. diff. infection at home, and support sessions that are free and available by phone to everyone needing a voice that understands able to guide families worldwide.

"The Worldwide Bake Sale for C.diff. Awareness campaign was insight-based. We know that the health message alone does not work, and felt that making our message appearance-based, with personal participation it would make the educational facet more relevant to our audiences," states Nancy C Caralla, Executive Director. "Who doesn't like to enjoy Grandma's chocolate chip cookies? Sharing, caring, and bringing it face-to-face with a blend of history is the recipe of our success in promoting C. difficile infection prevention, treatments, environmental safety, and support worldwide."

About the C Diff Foundation:

The C Diff Foundation, a 501(c)(3) established 2012, is comprised of 100 percent volunteering professionals dedicated at supporting public health through education and advocating for C. difficile infection (CDI) prevention, treatments, environmental safety, and support worldwide.

The Foundress, Nancy C. Caralla, a Nurse diagnosed and treated for Clostridium difficile (C. diff.) infections and witnessing the loss of her father to C. difficile infection involvement, Nancy recognized the need for greater awareness through education, about research being conducted by the government, industry, and academia and better advocacy on behalf of patients, healthcare professionals, and researchers worldwide working to address the public health threat posed by this devastating, life-threatening infection.

For information please visit http://www.cdifffoundation.org/

Media Contact Person: Nancy Caralla, ncaralla@cdifffoundation.org

*PHOTO for media: Send2Press.com/mediaboom/17-0504s2p-cdiffbake-300dpi.jpg

C Diff Foundation announces its "Bake Sale for C.diff. Awareness," a month-long campaign beginning May 2017 in Florida and continuing in N.J., N.C., and across the USA to India, and Italy featuring education and advocacy on health care topics pertaining to the most common pathogen identified as a leading healthcare-associated infection (HAI) in U.S. hospitals alone: Clostridium difficile.

International Healthcare Experts Gather Nov. 9-10 in Las Vegas to Discuss Global Problems Around Leading Healthcare-acquired Infection Clostridium difficile

LAS VEGAS, Nev. /ScoopCloud/ -- C Diff Foundation's 5th Annual International C.diff. Awareness Conference and Health EXPO will be hosted in Las Vegas, Nev. on November 9 & 10, 2017 at UNLV-Thomas and Mack Center. A panel of C. diff. survivors will join world-renowned experts delivering presentations on health care topics pertaining to the most common pathogen identified, a leading healthcare-associated infection (HAI) in U.S. hospitals alone: Clostridium difficile (C.diff.).

Nearly half a million Americans suffer from Clostridium difficile (C. diff.) infections in a single year according to a study released February 2015 by the Centers for Disease Control and Prevention (CDC). About 15,000 deaths were estimated to be directly attributable to C. diff. infections.

Previous studies indicate that C. diff. has become the most common microbial cause of healthcare-associated infections found in U.S. hospitals driving up costs to $4.8 billion each year.

Bringing medical professional guest speakers together, such as Dale Gerding, MD, FACP, FIDSA, Conference Chair and Professor of Medicine at Loyola University Chicago Stritch School of Medicine in Maywood, Illinois and Research Physician at the Edward Hines Jr. VA Hospital, with internationally recognized experts on healthcare-associated infections and the prevention of antimicrobial resistance - provides an educational opportunity for healthcare professionals and those sharing common interests. Presentations will be focused on, but not limited to Clostridium difficile (C.diff.) Prevention, Treatments, Diagnostics, Research, Clinical trials, Microbiome research, Infection Prevention, Irritable Bowel Syndrome treatments and clinical trials, Environmental Safety, Fecal Microbiota Restoration, Antibiotic Stewardship.

The 5th Annual International C.diff. Awareness Conference and Health EXPO will commence on November 9 & 10, 2017, Thomas and Mack Center, UNLV. Shuttle service provided for guests of Embassy Suites Convention Center Hotel, 3600 Paradise Road, Las Vegas, NV 89169 (Hotel Phone: 1 - (702)-947-7156).

The C Diff Foundation is grateful for its alliances; the corporations and organizations in alignment with their mission who join them in raising C. diff. awareness worldwide. A sincere thank you to the Sponsors and Exhibitors of the 5th Annual International C. diff. Awareness Conference and Health EXPO: Diamond Sponsor: Synthetic Biologics.

Gold Sponsors: Clorox Healthcare, Seres Therapeutics, ROCHE, Rebiotix, Nestle Health Science, Xenex. Silver Sponsors: SporeGen, Tru-D. This conference is supported through an educational grant from Sanofi Pasteur US.

Additional information and registration - Early Bird Registration Through June 1:
https://cdifffoundation.org/registration/

"None of us can do this alone, All of us can do this together," says Nancy C. Caralla.

About the C Diff Foundation:

The C Diff Foundation, a 501(c)(3) established 2012, comprised of 100% volunteering professionals dedicated at supporting public health through education and advocating for C. difficile infection (CDI) prevention, treatments, environmental safety, and support worldwide. The Foundress, Nancy C. Caralla, a Nurse diagnosed and treated for Clostridium difficile (C. diff.) infections and witnessing the loss of her father to C. difficile infection involvement, Nancy recognized the need for greater awareness through education, about research being conducted by the government, industry, and academia and better advocacy on behalf of patients, healthcare professionals, and researchers worldwide working to address the public health threat posed by this devastating, life-threatening infection.

More information: https://cdifffoundation.org/

Media Contact: ncaralla@cdifffoundation.org

C Diff Foundation's 5th Annual International C.diff. Awareness Conference and Health EXPO will be hosted in Las Vegas, Nev. on November 9 & 10, 2017 at UNLV-Thomas and Mack Center. A panel of C. diff. survivors will join world-renowned experts delivering presentations on health care topics pertaining to the most common pathogen identified, a leading healthcare-associated infection (HAI) in U.S. hospitals alone: Clostridium difficile (C.diff.).

C Diff Foundation’s 4th Annual International Raising C. diff. Awareness Conference and Health Expo 2016

TAMPA, Fla., May 6, 2016 (SEND2PRESS NEWSWIRE) -- The C Diff Foundation "International Raising C. diff. Awareness" Conference and Health Expo will be hosted in Atlanta on Sept. 20, 2016 featuring world-renowned experts delivering presentations on health care topics pertaining to the most common pathogen identified, a leading healthcare-associated infection (HAI) in U.S. hospitals alone: Clostridium difficile (C. diff.).

"Nearly half a million Americans have suffered from a Clostridium difficile, or C. diff., infection -- and it killed 29,000 people in 2011," says Nancy C. Caralla, founder of the C Diff Foundation.

According to a study released by the Centers for Disease Control and Prevention (CDC), C. diff. is a leading cause of infectious disease death worldwide. Previous studies indicate that C. diff. has become the most common microbial cause of healthcare-associated infections found in U.S. hospitals driving up costs to $4.8 billion each year in excess health care costs in acute care facilities alone.

Bringing medical professional guest speakers together, such as Dr. Clifford McDonald, MD from the Centers of Disease Control and Prevention (CDC), one of the leading government healthcare organizations in the U.S., and internationally recognized experts on healthcare-associated infections and the prevention of antimicrobial resistance - provides an educational opportunity for healthcare professionals and those sharing common interests.

Presentations will be focused on, but not limited to, Clostridium difficile (C. diff.) Prevention, Treatments, Research, Clinical trials and Studies, Microbiome research, Infection Prevention, Environmental Safety, Fecal Microbiota Restoration and Transplants, Antibiotic Resistance and Stewardship.

WHEN AND WHERE:
"International Raising C. diff. Awareness" Conference and Health Expo will commence on Tuesday, September 20, 2016; 7:30 a.m. to 5 p.m. Eastern Time at the DoubleTree by Hilton Hotel - Atlanta Airport, 3400 Norman Berry Drive, Atlanta, GA 30344 (Hotel Phone: 1-404-763-1600).

Sponsors include: Clorox Healthcare, Synthetic Biologics, Roche, XBiotech, CoreShield, SporGen. This conference is supported through an educational grant from Sanofi Pasteur US.

Additional information and registration can be found here: https://cdifffoundation.org/2016events/

"None of us can do this alone - All of us can do this together," adds Caralla.

About the C Diff Foundation:

The C Diff Foundation, a 501(c)(3) non-profit, Founded in 2012 by Nancy C. Caralla, a nurse who was diagnosed and treated for Clostridium difficile (C. diff.) infections. Through her own journey and the loss of her father to C. difficile infection involvement, Nancy recognized the need for greater awareness through education, about research being conducted by the government, industry, and academia and better advocacy on behalf of patients, healthcare professionals, and researchers worldwide working to address the public health threat posed by this devastating, life-threatening infection.

About The C diff Foundation Foundress, Executive Director:

Nancy C Caralla, hosts "C. diff. Spores and More" Global Broadcasting Network, and shares in a team focus on educating, and advocating for C. diff. infection prevention, treatments, and environmental safety -- and more -- worldwide.

For information please visit https://www.cdifffoundation.org/.

For media queries, contact: Nancy Caralla at ncaralla@cdifffoundation.org.

*PHOTO: Send2Press.com/mediaboom/16-0406-atlantaskyline-300dpi.jpg

Twitter: @cdiffFoundation #CdiffAwareness

To view the original version on Send2Press Newswire, visit: https://www.send2press.com/newswire/c-diff-foundation-4th-annual-international-raising-c-diff-awareness-conference-and-health-expo-2016-2016-0506-01.shtml.

NEWS SOURCE C Diff Foundation :: This press release was issued on behalf of the news source (who is solely responsible for its accuracy) by and Copr. © 2016 Send2Press® Newswire, a service of Neotrope®.

Taking Aim at Superbugs Discussed on C diff Spores and More Global Broadcasting Network with Dr Clifford McDonald of CDC

TAMPA, Fla., March 17, 2016 (SEND2PRESS NEWSWIRE) -- C Diff Foundation, "C. diff. Spores and More," Global Broadcasting Network - innovative and educational interactive healthcare talk radio show discusses taking aim at "superbugs" and the latest Vital Signs Report results with guest Dr. Clifford McDonald, MD on Tuesday, March 22, 2016 at 10 a.m. Pacific Time on VoiceAmerica Health and Wellness Channel.

Bringing guests together, such as Dr. Clifford McDonald, MD from the Centers of Disease Control and Prevention (CDC), one of the leading government healthcare organizations in the U.S., and internationally recognized experts on healthcare-associated infections, and the prevention of antimicrobial resistance has built a loyal listenership and continue to inform and educate listeners worldwide.

"C.diff. Spores and More" is broadcast live every Tuesday at 10 a.m. Pacific Time on the VoiceAmerica Health and Wellness channel, officially sponsored by Clorox Healthcare. Archived "C. diff. Spores and More" shows can be found here: http://www.voiceamerica.com/show/2441/c-diff-spores-and-more .

The Centers of Disease Control and Prevention (CDC) sounds the alarm on the danger of modern medicine returning to a time when simple infections were often fatal. As the latest Vital Signs Report shows, much progress has been made in our hospitals and healthcare facilities to protect patients from healthcare-associated infections. But, more work needs to be done, because many of these infections are caused by antibiotic-resistant bacteria which are difficult, if not impossible to treat.

CDC believes clinicians are key to national progress in preventing infections. They have the power to change the direction of antibiotic resistance each and every time they care for their patients. It requires taking the appropriate steps every time.

"We are in a race to slow resistance, and we can't afford to let the 'superbugs' outpace us, especially in healthcare settings," stated Dr. McDonald, MD.

About the C Diff Foundation:

The C Diff Foundation, a 501(c)3 non-profit, was founded in 2012 by Nancy C. Caralla, a nurse who was diagnosed and treated for Clostridium difficile (C. diff.) infections. Through her own journey and the loss of their father to C. difficile infection involvement, Nancy recognized the need for greater awareness through education about research being conducted by the government, industry, and academia and better advocacy on behalf of patients, healthcare professionals, and researchers worldwide working to address the public health threat posed by this devastating infection.

About The C diff Foundation Executive Director:

Nancy C Caralla, hosts "C. diff. Spores and More" Global Broadcasting Network with a team focus on educating, and advocating for C. diff. infection prevention, treatments, and environmental safety - and more -- worldwide.

For information please visit http://www.cdifffoundation.org/.

Media Contact Person: Nancy Caralla, ncaralla@cdifffoundation.org.

* IMAGE for media: Send2Press.com/mediaboom/16-0317-Cdiff-Awareness-300dpi.jpg

* LOGO for media: Send2Press.com/mediaboom/15-0723-cdiff-fdn-300dpi.jpg

TWITTER: @cdiffFoundation #Cdiff @VoiceAmericaTRN

To view the original version on Send2Press Newswire, visit: https://www.send2press.com/newswire/Taking-Aim-at-Superbugs-Discussed-on-C-diff-Spores-and-More-Global-Broadcasting-Network-with-Dr-Clifford-McDonald-of-CDC-2016-0317-04.shtml.